Clinical Labs Of Hawaii Wailuku -Mmg

CLIA Laboratory Citation Details

2
Total Citations
6
Total Deficiencyies
6
Unique D-Tags
CMS Certification Number 12D0619547
Address 2180 Main Street 2nd Floor, Wailuku, HI, 96793
City Wailuku
State HI
Zip Code96793
Phone(808) 243-2313

Citation History (2 surveys)

Survey - February 14, 2025

Survey Type: Standard

Survey Event ID: PJXG11

Deficiency Tags: D5791 D6020 D6032

Summary:

Summary Statement of Deficiencies D5791 ANALYTIC SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1289(a)(c) (a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess, and when indicated, correct problems identified in the analytic systems specified in 493.1251 through 493.1283. This STANDARD is not met as evidenced by: The surveyor's review of laboratory quality assurance procedures and an interview with the one testing personnel on February 14, 2025 at 10:30 AM revealed the laboratory failed to follow its written policies and procedures for an ongoing mechanism to monitor, assess, and correct analytic system problems. The laboratory performed an annual volume of 39 iSTAT Troponin I tests, 834 manual differentials, 1,586 urine microscopic examinations, and 49 post vasectomy semen examinations. The findings include: 1. The testing personnel stated documentation for 2 of 8 quality indicators listed in the laboratory PSC Quality Indicators procedure was not available fore review, e.g., Quality indicator #3 "Monitoring patient wait times and taking action to improve"and Quality indicator #4 "Evaluating yearly CLH Patient Satisfaction Surveys". 2. The testing personnel stated 4 of 16 quality indicators listed in the laboratory Appendix, Quality Assurance Indicators CLH-Wailuku-MMG Laboratory were not performed, e.g., Semiannual Abbott iSTAT: Correlation studies for Troponin I with MMMC lab, Semiannual Interlab proficiency surveys (Differential), Semiannual Interlab proficiency surveys (Urinalysis), and Microscope Annual maintenance sent to MMMC. D6020 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(5) (e)(5) Ensure that the quality control and quality assessment programs are established and maintained to assure the quality of laboratory services provided and to identify Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- failures in quality as they occur; This STANDARD is not met as evidenced by: The surveyor's review of laboratory quality assurance procedures and an interview with the one testing personnel on February 14, 2025 at 10:30 AM revealed the laboratory director failed to ensure that the laboratory's quality assessment program was maintained to assure the quality of the routine chemistry, urinalysis, and hematology testing services it provides. The findings include: 1. The laboratory failed to follow its written policies and procedures for an ongoing mechanism to monitor, assess, and correct analytic system problems. See D tag D5791. D6032 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(14) (e)(14) Specify, in writing, the responsibilities and duties of each consultant and each person, engaged in the performance of the preanalytic, analytic, and postanalytic phases of testing, that identifies which examinations and procedures each individual is authorized to perform, whether supervision is required for specimen processing, test performance or results reporting, and whether consultant or director review is required prior to reporting patient test results. This STANDARD is not met as evidenced by: The surveyor's review of laboratory policies, procedures, and records, and an interview with the one testing personnel on February 14, 2025 at 10:00 AM revealed the laboratory director failed to specify in writing the responsibilities and duties of each consultant, and testing personnel performing the preanalytic, analytic, and post analytic phases of its testing. The findings include: 1. The laboratory Form CMS-209 Laboratory Personnel Report (CLIA) lists three Technical Consultants (TC). The one testing personnel stated that TC #3 served as the interim laboratory director effective April 2024 and the laboratory director on the Form CMS-209 had not been to the laboratory in 2024 up until the current survey date. The List of Designees Annual Review sheet stated "Reason for modification: Updated Laboratory Director". TC #3 approved the modification on May 1, 2024. Documentation of the responsibilities and duties of TC #3 was not available for surveyor review. 2. Documentation of testing personnel responsibilities and duties that identifies the procedure each individual is authorized to perform, whether supervision is required for specimen processing, test performance or results reporting, and whether consultant or director review is required prior to reporting patient test results was not available for surveyor review. The one laboratory testing personnel performed an annual volume of 39 iSTAT Troponin I tests, 834 manual differentials, 1,586 urine microscopic examinations, and 49 post vasectomy semen examinations. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - April 26, 2023

Survey Type: Standard

Survey Event ID: JEM511

Deficiency Tags: D2123 D5293 D6019

Summary:

Summary Statement of Deficiencies D2123 HEMATOLOGY CFR(s): 493.851(c) Failure to participate in a testing event is unsatisfactory performance and results in a score of 0 for the testing event. Consideration may be given to those laboratories failing to participate in a testing event only if-- (1) Patient testing was suspended during the time frame allotted for testing and reporting proficiency testing results; (2) The laboratory notifies the inspecting agency and the proficiency testing program within the time frame for submitting proficiency testing results of the suspension of patient testing and the circumstances associated with failure to perform tests on proficiency testing samples; and (3) The laboratory participated in the previous two proficiency testing events. This STANDARD is not met as evidenced by: Based on a review of CAP hematology proficiency testing records and an interview with the on-site testing personnel on April 26, 2023 at 11:30 AM, it was determined that the laboratory failed to participate in the second FH1-B testing event of 2022 resulting in a score of 0%. The laboratory performed an annual volume of 5757 tests in 2022. The findings include: 1. The on-site testing personnel confirmed cell ID or WBC diff, RBC, HCT, HGB, WBC and platelet testing were not performed on 5 of 5 event samples (FH1-06, FH1-07, FH1-08, FH1-09, FH1-10). 2. The on-site testing personnel confirmed the laboratory failed to notify the CLIA state agency and the CAP proficiency testing program within the time frame for submitting proficiency testing results of the suspension of patient testing and the circumstances associated with the failure to perform proficiency testing. 3. The on-site testing personnel confirmed the laboratory failed to follow its External Proficiency Testing Procedure, Responsibilities to CMS. An initial letter of explanation and a notification letter "when testing was resumed and PT has been performed satisfactorily, either on- schedule or off-schedule" was not sent to the CIA state agency. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- D5293 GENERAL LABORATORY SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1239(b)(c) (b) The general laboratory systems quality assessment must include a review of the effectiveness of

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access